Histopathology of castration-resistant prostate cancer confirms changes in bone metastasis during radium-223 treatment: A case report

Masato Dobashi; Dai Kouguchi; Yukiko Kanetsuna; Junichiro Ishii

doi:10.1016/j.eucr.2020.101230

Histopathology of castration-resistant prostate cancer confirms changes in bone metastasis during radium-223 treatment: A case report

Urol Case Rep. 2020 May 3:32:101230. doi: 10.1016/j.eucr.2020.101230. eCollection 2020 Sep.

Authors

Masato Dobashi¹, Dai Kouguchi¹, Yukiko Kanetsuna², Junichiro Ishii¹

Affiliations

¹ Department of Urology, International University of Health and Welfare Atami Hospital, 13-1 Higashikaigan-cho, Atami, Shizuoka, 413-0012, Japan.
² Department of Pathology, International University of Health and Welfare Atami Hospital, 13-1 Higashikaigan-cho, Atami, Shizuoka, 413-0012, Japan.

Abstract

Radium-223 is used for treating castration-resistant prostate cancer with bone metastases. Here, we report the case of a 76-year-old man diagnosed with castration-resistant prostate cancer with bone metastases who was started on radium-223. Although the patient ultimately died from causes unrelated to the treatment before starting the third treatment course, we observed that radium-223 was more effective in areas closer to the bone cortex than in deeper tumor regions. Through histopathological analysis, we provide important mechanistic insights on the therapeutic effect of radium-223 in human prostate cancer bone metastases.

Keywords: ALP, alkaline phosphatase; Bone metastasis; CAB, combined androgen blockade; CRPC, castration-resistant prostate cancer; Castration-resistant prostate cancer; Histopathology; OS, overall survival; PSA, prostate-specific antigen; RANKL, receptor activator of nuclear factor-κB ligand; Ra-223, radium-223; Radium-223; SRE, skeletal related event.

Publication types

Case Reports